October 15th 2024
Research from ESMO 2024 focused on the relationship between survival outcomes and medication adherence.
September 16th 2024
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Transforming Small Cell Lung Cancer Management With DLL3-Targeted Therapies
November 13, 2024 | 1:00 & 8:00 PM ET
View More
Emerging Trends in the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma Treatment
1.0 Credits / Oncology
View More
Balancing Anticancer Efficacy and Cardiovascular Safety: A Pharmacist's Guide
1.0 Credits / Oncology
View More
Balancing the Benefits and Risks of Asparaginase Treatment in Adults and Young Adults With Acute Lymphoblastic...
1.0 Credits / Oncology
View More
Maximizing Efficacy and Minimizing Toxicity of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
1.0 Credits / Oncology
View More
Optimizing Use of Small Molecule Inhibitors in Chronic Lymphocytic Leukemia: Strategies for Safe and Effective...
1.0 Credits / Hematology, Oncology
View More
Recognizing the Signs and Symptoms of Cytokine Release Syndrome in Novel Cancer Therapies: Strategies for Onco...
1.0 Credits / Oncology
View More
PARP Inhibitors for Ovarian Cancer: An Oncology Pharmacist's Guide to the Latest Clinical Advancements
1.0 Credits / Oncology
View More
Revolutionizing the Treatment of Endometrial Cancer by Leveraging the Potential of Immune Checkpoint Inhibitor...
1.0 Credits / Oncology
View More
Navigating the Evolving Treatment Landscape of Metastatic Renal Cell Carcinoma
2.0 Credits / Nephrology, Oncology
View More
Advances in the Treatment of Metastatic Renal Cell Carcinoma: New Horizons in Targeted Therapies
1.0 Credit / Genitourinary Cancer, Oncology
View More
Optimizing Asparaginase Use in Acute Lymphoblastic Leukemia: A Comprehensive Program on Safety and Efficacy
1.0 Credit / Genitourinary Cancer, Oncology
View More
Navigating Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatment: An Interdisciplinary Approach
1.5 Credits / Oncology
View More
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and...
December 18, 2024 | 1:00 & 8:00 PM ET
View More
Mastering Oncology Clinical Trials: Immune Checkpoint Inhibitors in Frontline Metastatic Non–Small Cell Lung C...
1.5 Credits / Lung Cancer, Oncology
View More
Navigating the Evolving Landscape of HER2-Positive Early-Stage Breast Cancer: Considerations for Managed Care
2.0 Credits / Breast Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
1.0 Credits / Hematologic Cancer, Oncology
View More
Revolutionizing Multiple Myeloma Care: CAR T-Cell Therapy, Bispecific Antibodies, and Patient-Centered Strateg...
1.0 Credit / Oncology, Hematologic Cancer
View More
Managed Care Approaches to Improve Outcomes in Frontline Therapy for Renal Cell Carcinoma
2.0 Credits / Oncology
View More
Challenges in Treatment of Desmoid Tumors and Managed Care Solutions
0.5 Credit / Oncology
View More
Desmoid Tumors: What Managed Care Professionals Need to Know to Manage These Unpredictable Tumors, featuring a...
2.0 Credits / Oncology
View More
Balancing Innovation and Implementation: A Comprehensive Approach to CAR T, Bispecific Antibodies, and Operati...
1.0 Credit / Hematologic Cancer, Oncology
View More
Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists
1.0 Credit / Hematologic Cancer, Oncology
View More
Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based C...
1.0 Credit / Hematologic Cancer, Oncology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes: Bridging Clinical Innovation and Pract...
1.0 Credit / Hematologic Cancer, Oncology
View More
Advancements in Early-Stage Breast Cancer: The Role of Oncology Pharmacists in Treatment Optimization
1.0 Credit / Breast Cancer, Women’s Health, Oncology
View More
Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
1.0 Credit / Hematologic Cancer, Oncology
View More
Precision Oncology in Practice: Transforming Non–Small Cell Lung Cancer Care Through Advanced Biomarker Testin...
0.75 Credit / Oncology
View More
ASCO20 Virtual: Study Assesses COVID-19 Clinical Data, Finds Cancer Mortality Links
May 28th 2020The findings, which were presented virtually in the 2020 ASCO Virtual Scientific Program, included the association between treatment with hydroxychloroquine plus azithromycin and increased risk of death.
Trastuzumab Deruxtecan Granted Breakthrough Designation for HER2-Mutant Metastatic NSCLC
May 19th 2020Officials with the FDA have granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu, AstraZeneca and Daiichi Sankyo) for the treatment of HER2-mutant metastatic non-small cell lung cancer (NSCLC).
Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Unresectable or Metastatic Breast Cancer
May 13th 2020Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.
Darolutamide for Non-Metastatic Castration-Resistant Prostate Cancer
May 11th 2020In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).
FDA OKs Niraparib for Frontline Maintenance Treatment of Ovarian Cancer
April 30th 2020Officials with the FDA approved niraparib (Zejula, GlaxoSmithKline), a once-daily, oral monotherapy, for the first-line maintenance treatment of platinum-responsive advanced ovarian cancer regardless of biomarker status.
FDA OKs New Treatment for Advanced or Metastatic HER2-Positive Breast Cancer
April 17th 2020Officials with the FDA today approved tucatinib (Tukysa, Seattle Genetics) in combination with chemotherapy trastuzumab and capecitabine for the treatment of adults with advanced forms of HER2-positive breast cancer.
A Conversation About Cancer Care During COVID-19: Part 2
April 14th 2020In part 2 of our video interview, Robert Brunault, PharmD, a clinical pharmacy specialist in hematology and oncology at Rhode Island Hospital and the Lifespan Cancer Institute, discussed drug shortages, FDA emergency use authorizations, and the biggest concerns for pharmacists.
A Conversation About Cancer Care During COVID-19
April 10th 2020In a video interview with Drug Topics®, Robert Brunault, PharmD, a clinical pharmacy specialist of hematology and oncology at Rhode Island Hospital and Lifespan Cancer Institute, answers questions about how the COVID-19 pandemic affects patients undergoing treatment for cancer.